Taq DNA polymerase variants with increased reverse transcriptase activity

By developing Taq DNA polymerase mutants that enhance reverse transcription activity, the problem of Taq DNA polymerase unstable activity during RNA reverse transcription was solved, efficient cDNA amplification under standard reaction conditions was achieved, and RT-PCR was improved The efficiency and accuracy of the detection.

CN119060979AInactive Publication Date: 2024-12-03WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410630200.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-21
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Taq DNA polymerases are unstable in RNA reverse transcription, limiting the efficiency and accuracy of RT-PCR, and it is difficult to effectively amplify cDNA under standard reaction conditions.

Method used

An engineered Taq DNA polymerase mutant with enhanced reverse transcriptase activity was developed to increase its cDNA amplification capability under standard reaction conditions by adding tag sequence GSGSSGHHHHHHH and specific amino acid substitutions at the C-terminus, reducing the additional Resistance to reverse transcriptase.

Benefits of technology

The efficiency and accuracy of RT-PCR detection of RNA was significantly improved, the complexity of the reaction scheme was reduced, and the buffer composition was optimized, so that the single enzyme system could work robustly under standard conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060979A_ABST
    Figure CN119060979A_ABST
Patent Text Reader

Abstract

In some embodiments, Taq DNA polymerase mutants that exhibit reverse transcriptase activity as compared to wild-type polymerases are engineered, characterized, and selected via a polymerase chain reaction that is visualized via electrophoresis on an agarose gel. The initial screening is followed with a probe-based qualitative real-time fluorescent quantitative PCR (qPCR) that detects specific ribonucleic acid (RNA) target sequences with a typical reverse transcription cycling scheme. The engineered variants can present robust cDNA from an RNA target substrate and amplify the cDNA under standard reaction conditions without the help of an added reverse transcriptase.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Patent Application No. 18 / 323,660, filed on May 25, 2023, the entire contents of which are incorporated herein by reference.

[0003] Sequence Listing

[0004] This application contains a sequence listing in ASCII format that has been submitted electronically and is hereby incorporated by reference in its entirety. This ASCII copy was created on 2022 / 4 / 21, is named ABcl-TaqRT(generic)_SL.txt, and is 1.653 megabytes in size. Background Art

[0005] Real-time RT-PCR is a method for detecting RNA in a sample via the detection of a fluorescent signal that increases over time as amplicons are produced in a qPCR reaction. Currently, the most widely known application of RT-PCR is the detection of viral genetic material, such as the presence of SARS-CoV2 (COVID-19), in patient samples during diagnostic laboratory assays. RT-PCR is the standard for RNA target detection in molecular biology, medicine, and forensic research.

[0006] Taq DNA polymerase is commonly used in molecular biology to extend nucleic acid amplicons in polymerase chain reaction (PCR). In PCR, a specified DNA segment (amplicon) is amplified by repeated cycles of three steps: denaturation, annealing, and elongation / extension of the amplicon. In the case of qualitative real-time PCR (qPCR), the fluorescent signal generated by a dye or probe allows data to be collected during the PCR cycles so that target amplification can be measured and recorded. Probe-based chemistry utilizes fluorescently labeled target-specific probes that release a reporter dye only when bound to the target sequence, allowing real-time detection of target amplification as the intensity of the fluorescent signal increases.

[0007] RT-PCR allows for the detection and amplification of RNA substrates. When a reverse transcriptase is included in the qPCR reaction, detection of RNA can be achieved via an additional initial cycling step in which the reverse transcriptase produces complementary DNA (cDNA) to the RNA substrate; the cDNA can then be amplified for quantification by an accompanying DNA polymerase. Current RT-PCR protocols rely on a combination of a reverse transcriptase and a polymerase to generate data. In most cases, Taq polymerase is limited to the amplification of DNA isoforms; the few instances in which it is able to produce cDNA from RNA substrates typically rely on very specific buffers and protocols. 1,2, or rely on mutation of aspartic acid at amino acid position 732. Overall, Taq activity in these cases is typically not as robust as Taq activity of reverse transcriptase. In order to generate a more reliable Taq polymerase with intrinsic reverse transcriptase activity, Taq DNA polymerase mutants were generated using site-directed mutagenesis, and among them, a variety of mutants were found to be able to quickly and consistently convert RNA substrates into DNA products for PCR or RT-PCR purposes. Summary of the invention

[0008] The present invention relates to engineered Taq DNA polymerase mutants that exhibit greater reverse transcriptase activity than wild-type polymerase. The Taq DNA polymerase mutants listed in the description of the drawings and the detailed description are identified as having such enhanced reverse transcriptase activity, each of which has a tag sequence added at the C-terminus: GSGSSGHHHHHH (SEQ ID NO: 315), and each of which has a substitution at the indicated position (and wherein the DNA sequence of each mutant is followed by an odd sequence identifier, and the amino acid sequence of each mutant is followed by an even identifier). The present invention further includes a Taq DNA polymerase amino acid sequence having at least one of the above mutations, but wherein the remainder of the Taq DNA polymerase mutant amino acid sequence has only conservative substitutions, so that the molecule has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identity with the corresponding Taq DNA polymerase mutant amino acid sequence in the sequence table (hereinafter referred to as a "variant sequence").

[0009] The present invention also includes the DNA sequence preceding each amino acid sequence of the above mutants (i.e., SEQ ID NO: respectively), and also includes the aforementioned DNA sequence and other degenerate nucleic acid sequences (collectively referred to as "degenerate nucleic acid sequences"), which encode (i) each of the above Taq DNA polymerase mutants, and (ii) the amino acid sequence of any one of the variant sequences.

[0010] The present invention further includes vectors incorporating any degenerate nucleic acid sequence; and cells transformed with any such vector or degenerate nucleic acid sequence and capable of expressing any of the above Taq DNA polymerase mutant amino acid sequences or variant sequences.

[0011] The present invention also includes a composition or kit comprising any of the above Taq DNA polymerase mutant amino acid sequence or variant sequence, a degenerate nucleic acid sequence, or a vector incorporating such a degenerate nucleic acid sequence. The present invention also includes a method for amplifying a target nucleic acid, wherein any of the above Taq DNA polymerase mutant or variant sequences is employed in a reaction mixture designed to amplify the target nucleic acid, and the reagent mixture is subjected to conditions for amplifying the target nucleic acid.

[0012] Unlike wild-type Taq DNA polymerase, which exhibits limited reverse transcriptase activity only under very stringent reaction conditions, engineered variants can render robust cDNA from RNA target substrates and amplify the cDNA under standard reaction conditions without the aid of added reverse transcriptase. Removing the requirement for an additional reverse transcriptase in the qPCR protocol can significantly improve the efficiency of detecting target RNA via RT-qPCR, while also reducing protocol complexity, thereby allowing for increased protocol optimization, and unifying buffer compositions to those that are most efficient for a single enzyme. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figures 1 to 5 It is the gel image of the cDNA amplification comparison (thereby indicating reverse transcriptase activity) from the Taq DNA wild-type and the mutants identified in each figure, and described in the following accompanying drawing overview. Each composite gel shows WT and mutant activity aligned with low molecular weight ladder marks (the leftmost column of each figure). The mutants and their DNA sequence dna (odd identifiers) and their protein sequences (even identifiers) shown in every kind of gel are shown below.

[0014] Figure 1A gel showing the activity comparison of reverse transcriptase WT (SEQ ID NO:1; SEQ ID NO:2) and the following mutants: E9K (SEQ ID NO:3; SEQ ID NO:4), L15S (SEQ ID NO:5; SEQ ID NO:6), D18R (SEQ ID NO:7; SEQ ID NO:8), H20E (SEQ ID NO:9; SEQ ID NO:10), H21E (SEQ ID NO:11; SEQ ID NO:12), K31E (SEQ ID NO:13; SEQ ID NO:14), R37D (SEQ ID NO:15; SEQ ID NO:16), F66A (SEQ ID NO:17; SEQ ID NO:18), K82E (SEQ ID NO:19; SEQ ID NO:20), A83F (SEQ ID NO:21; SEQ ID NO:22), R85D (SEQ ID NO:23; SEQ ID NO:24), P87G (SEQ ID NO:25; SEQ ID NO:26), P89G (SEQ ID NO:27; SEQ ID NO:28), E90K (SEQ ID NO:29; SEQ ID NO:30), F92A (SEQ ID NO:31; SEQ ID NO:32), I99S (SEQ ID NO:33; SEQ ID NO:34), E101K (SEQ ID NO:35; SEQ ID NO:36), L102S (SEQ ID NO:37; SEQ ID NO:38), L108S (SEQ ID NO:39; SEQ ID NO:40), A109F (SEQ ID NO:41; SEQ ID NO:42), R110D (SEQ ID NO:43; SEQ ID NO:44), G115P (SEQ ID NO:45; SEQ ID NO:46), S124I (SEQ ID NO:47; SEQ ID NO:48), I138S (SEQ ID NO:49; SEQ ID NO:50), V155S (SEQ ID NO:51; SEQ ID NO:52) and L156S (SEQ ID NO:53; SEQ ID NO:54).

[0015] Figure 2: A gel showing the activity comparison of reverse transcriptase WT (SEQ ID NO:1; SEQ ID NO:2) and the following mutants: H157E (SEQ ID NO:55; SEQ ID NO:56), T164I (SEQ ID NO:57; SEQ ID NO:58), L168S (SEQ ID NO:59; SEQ ID NO:60), R183D (SEQ ID NO:61; SEQ ID NO:62), G187P (SEQID NO:63; SEQ ID NO:64), E189A (SEQ ID NO:65; SEQ ID NO:66), E189I (SEQ ID NO:67; SEQ ID NO:68), E189K (SEQ ID NO:69; SEQ ID NO:70), E189S (SEQ ID NO:71; SEQ ID NO:72), K202E (SEQ ID NO:73; SEQ ID NO:74), L233S (SEQ ID NO:85; SEQ ID NO:86), E230A (SEQ ID NO:75; SEQ ID NO:76), E230C (SEQ ID NO:77; SEQ ID NO:78), E230M (SEQ ID NO:79; SEQ ID NO:80), E230Q (SEQ ID NO:81; SEQ ID NO:82), E230V (SEQ ID NO:83; SEQ IDNO:84), L233S (SEQ ID NO:85; SEQ ID NO:86), H235E (SEQ ID NO:87; SEQ ID NO:88), M236S (SEQ ID NO:89; SEQ ID NO:90), D237R (SEQ ID NO:91; SEQ ID NO:92), D244R (SEQID NO:93; SEQ ID NO:94), K247E (SEQ ID NO:95; SEQ ID NO:96), L281S (SEQ ID NO:97; SEQ ID NO:98), P291G (SEQ ID NO:99; SEQ ID NO:100), L294S (SEQ ID NO:101; SEQ IDNO:102), V310S (SEQ ID NO:103; SEQ ID NO:104), K314E (SEQ ID NO:105; SEQ ID NO:106), R349D (SEQ ID NO:107; SEQ ID NO:108), L379S (SEQ ID NO:109;SEQ ID NO: 110), S383I (SEQ ID NO: 111; SEQ ID NO: 112), Y394A (SEQ ID NO: 113; SEQ ID NO: 114), G395P (SEQ ID NO: 115; SEQ ID NO: 116), and A442F (SEQ ID NO: 117; SEQ ID NO: 118).;

[0016] Figure 3: Gel showing the activity comparison of reverse transcriptase WT (SEQ ID NO:1; SEQ ID NO:2) and the following mutants: E507G (SEQ ID NO:119; SEQ ID NO:120), E507I (SEQ ID NO:121; SEQ ID NO:122), E507L (SEQ ID NO:123; SEQ ID NO:124), E537W (SEQ ID NO:125; SEQ ID NO:126), T544I (SEQ ID NO:127; SEQ ID NO:128), P550G (SEQ ID NO:129; SEQ ID NO:130), D578F (SEQ ID NO:131; SEQ ID NO:132), D578R (SEQ ID NO:133; SEQ ID NO:134), D578T (SEQ IDNO:135; SEQ ID NO:136), D578Y (SEQ ID NO:137; SEQ ID NO:138), D732A (SEQ ID NO:139; SEQ ID NO:140), D732F (SEQ ID NO:141; SEQ ID NO:142), D732G (SEQ ID NO:143; SEQ IDNO:144), D732I (SEQ ID NO:145; SEQ ID NO:146), D732P (SEQ ID NO:147; SEQ ID NO:148), D732Q (SEQ ID NO:149; SEQ ID NO:150), D732S (SEQ ID NO:151; SEQ ID NO:152), E742A (SEQ ID NO:153; SEQ ID NO:154), E742G (SEQ ID NO:155; SEQ ID NO:156), E742H (SEQ ID NO:157; SEQ ID NO:158), E742I (SEQ ID NO:159; SEQ ID NO:160), E742M (SEQ IDNO:161; SEQ ID NO:162), E742P (SEQ ID NO:163; SEQ ID NO:164), E742S (SEQ ID NO:165; SEQ ID NO:166), E39K / E189K (SEQ ID NO:167; SEQ ID NO:168), E39K / E230K (SEQ ID NO:169; SEQ ID NO:170), E39K / E520K (SEQ ID NO:171;SEQ ID NO: 172), E39K / E537K (SEQ ID NO: 173; SEQ ID NO: 174), E39K / D578R (SEQ ID NO: 175; SEQ ID NO: 176), E39K / D732R (SEQ ID NO: 177; SEQ ID NO: 178), E39K / E742K (SEQ ID NO: 179; SEQ ID NO: 180), G46D / E189K (SEQ ID NO: 181; SEQ ID NO: 182) and G46D / E230K (SEQ ID NO: 183; SEQ ID NO: 184).;

[0017] Figure 4: Shown is a gel indicating a comparison of the activities of reverse transcriptase WT (SEQ ID NO: 1; SEQ ID NO: 2) and the following mutants: G46D / N384R (SEQ ID NO: 185; SEQ ID NO: 186), G46D / D578R (SEQ ID NO: 187; SEQ ID NO: 188), E189K / E230K (SEQ ID NO: 189; SEQ ID NO: 190), E189K / E520K (SEQ ID NO: 191; SEQ ID NO: 192), E189K / E537K (SEQ ID NO: 193; SEQ ID NO: 194), E189K / D578R (SEQ ID NO: 195; SEQ ID NO: 196), E189K / E742K (SEQ ID NO: 199; SEQ ID NO: 200), E230K / E520K (SEQ ID NO: 201; SEQ ID NO: 202), NO:202), E230K / E537K (SEQ ID NO:203; SEQ ID NO:204), E230K / D578R (SEQ ID NO:205; SEQ ID NO:206), E230K / D732R (SEQ ID NO:207; SEQ ID NO:208), E230K / E742K (SEQ ID NO:202) NO:209; SEQ ID NO:210), E537K / D578R (SEQ ID NO:219; SEQ ID NO:220), E537K / D732R (SEQ ID NO:221; SEQ ID NO:222), E537K / E742K (SEQ ID NO:223; SEQID NO:224), D732R / E742K (SEQ ID NO:229; SEQ ID NO:230), G46D / E189K / E230K (SEQ ID NO:231; SEQ ID NO:232), G46D / E189K / D578R (SEQ ID NO:233; SEQ ID NO:234), G46D / E189K / F667Y (SEQ ID NO:235; SEQ ID NO: 236), G46D / E189K / D732R (SEQ ID NO: 237; SEQ ID NO: 238), G46D / E230K / F667Y (SEQ ID NO: 239; SEQ ID NO: 240), G46D / E230K / D732R (SEQ ID NO: 241;SEQ ID NO:242), G46D / N384R / F667Y (SEQ ID NO:243; SEQ ID NO:244), G46D / D578R / F667Y (SEQ ID NO:245; SEQ ID NO:246), E189K / E230K / E520K (SEQ ID NO:247; SEQ ID NO:248), E189K / E230K / E537K (SEQ ID NO:249; SEQ ID NO:250), E189K / E230K / D578R (SEQ ID NO:251; SEQ ID NO:252), E189K / E230K / D732R (SEQ ID NO:253; SEQ ID NO:254), E189K / E230K / E742K (SEQ ID NO:255; SEQ ID NO:256), E189K / E520K / E537K (SEQ ID NO:257; SEQ ID NO:258), E189K / E520K / D578R (SEQ ID NO:259; SEQ ID NO:260), E189K / E520K / D732R (SEQ ID NO:261; SEQ ID NO:262), E189K / E520K / E742K (SEQ ID NO:263; SEQ ID NO:264), E189K / E537K / D578R (SEQ ID NO:265; SEQ ID NO:266), E189K / E537K / D732R (SEQ ID NO:267; SEQ ID NO:268), E189K / E537K / E742K (SEQ ID NO:269; SEQ ID NO:270), and E189K / D578R / D732R (SEQ ID NO:271; SEQ ID NO:272).;

[0018] Figure 5: Shown is a gel indicating a comparison of the activities of reverse transcriptase WT (SEQ ID NO: 1; SEQ ID NO: 2) and the following mutants: E189K / D578R / E742K (SEQ ID NO: 273; SEQ ID NO: 274), E189K / D732R / E742K (SEQ ID NO: 275; SEQ ID NO: 276), E230K / E520K / E537K (SEQ ID NO: 277; SEQ ID NO: 278), E230K / E520K / D578R (SEQ ID NO: 279; SEQ ID NO: 280), E230K / E520K / D732R (SEQ ID NO: 281; SEQ ID NO: 282), E230K / E520K / E742K (SEQ ID NO: 283; SEQ ID NO: 284), NO: 284), E230K / E537K / D578R (SEQ ID NO: 285; SEQ ID NO: 286), E520K / E537K / D578R (SEQ ID NO: 293; SEQ ID NO: 294), E230K / E537K / D732R (SEQ ID NO: 287; SEQ ID NO:288), E230K / D732R / E742K (SEQ ID NO:291; SEQ ID NO:292), E520K / E537K / D578R (SEQ ID NO:293; SEQ ID NO:294), E520K / E537K / D732R (SEQ ID NO:295; SEQ ID NO:296), E520K / D578R / D732R (SEQ ID NO:297; SEQ ID NO:298), E537K / D578R / D732R (SEQ ID NO:301; SEQ ID NO:302), E520K / D732R / E742K (SEQ ID NO:299; SEQ ID NO:300), E537K / D578R / E742K (SEQ ID NO:303; SEQID NO:304), E537K / D578R / E742K (SEQ ID NO:303; SEQ ID NO:304), D578R / D732R / E742K (SEQ ID NO:307; SEQ ID NO:308), G46D / E189K / E230K / F667Y (SEQ ID NO:309; SEQ ID NO:310) and G46D / E189K / D578R / F667Y (SEQ ID NO:311; SEQ ID NO:312). DETAILED DESCRIPTION

[0019] The term "biologically active fragment" refers to any fragment, derivative, homologue or analogue of a Taq DNA polymerase or variant sequence that has the in vivo or in vitro reverse transcriptase activity characteristic of the molecule. In some embodiments, a biologically active fragment, derivative, homologue or analogue of a mutant Taq DNA polymerase has any degree of biological activity of the mutant Taq DNA polymerase in any in vivo or in vitro assay.

[0020] In some embodiments, the biologically active fragment may optionally include any number of consecutive amino acid residues of a mutant Taq DNA polymerase or variant sequence. The present invention also includes polynucleotides encoding any such biologically active fragments and / or degenerate nucleic acid sequences.

[0021] Biologically active fragments can be derived from translation of post-transcriptional processing or alternative splicing RNA, or alternatively can be produced by engineering, batch synthesis or other suitable manipulations. Biologically active fragments include fragments expressed in natural or endogenous cells, and fragments produced in expression systems (such as bacteria, yeast, plants, insects or mammalian cells).

[0022] As used herein, the phrase "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid by another amino acid with common properties. A functional method for defining common properties between individual amino acids is to analyze the normalized frequency of amino acid changes between corresponding proteins of homologous organisms (Schulz (1979) Principles of Protein Structure [principles of protein structure], Springer-Verlag). According to such analysis, amino acid groups can be defined as groups in which amino acids are preferentially interchanged with each other and are therefore most similar to each other in terms of their effects on the overall protein structure (Schulz (1979) supra). Examples of amino acid groups defined in this manner may include: "charged / polar group", including Glu, Asp, Asn, Gln, Lys, Arg and His; "aromatic or cyclic group", including Pro, Phe, Tyr and Trp; and "aliphatic group", including Gly, Ala, Val, Leu, Ile, Met, Ser, Thr and Cys. Within each group, subgroups may also be identified. For example, the group of charged / polar amino acids can be subdivided into multiple subgroups, including: a "positively charged subgroup" including Lys, Arg, and His; a "negatively charged subgroup" including Glu and Asp; and a "polar subgroup" including Asn and Gln. In another example, the aromatic or cyclic group can be subdivided into multiple subgroups, including: a "nitrogen ring subgroup" including Pro, His, and Trp; a "phenyl subgroup" including Phe and Tyr. In another further example, the aliphatic group can be subdivided into multiple subgroups, including: a "large aliphatic non-polar subgroup" including Val, Leu, and Ile; a "aliphatic weakly polar subgroup" including Met, Ser, Thr, and Cys; and a "small residue subgroup" including Gly and Ala. Examples of conservative mutations include amino acid substitutions of amino acids within the above subgroups, such as, but not limited to: Lys for Arg, and vice versa, so that a positive charge can be maintained; Glu for Asp, and vice versa, so that a negative charge can be maintained; Ser for Thr, and vice versa, so that a free -OH can be maintained; and Gln for Asn, and vice versa, so that a free -NH2 can be maintained. A "conservative variant" is a polypeptide that includes one or more amino acids that have been substituted to replace one or more amino acids of a reference polypeptide (e.g., a polypeptide whose sequence is disclosed in a publication or sequence database, or whose sequence has been determined by nucleic acid sequencing) with an amino acid having common properties (e.g., belonging to the same amino acid group or subgroup as described above).

[0023] When referring to a gene, "mutant" means that the gene has at least one base (nucleotide) change, deletion or insertion relative to the native or wild-type gene. The mutation (change, deletion and / or insertion of one or more nucleotides) can be in the coding region of the gene, or can be in an intron, 3'UTR, 5'UTR or promoter region. As a non-limiting example, a mutant gene can be a gene with an insertion in the promoter region, which can increase or decrease the expression of the gene; it can be a gene with a deletion, resulting in the production of a non-functional protein, a truncated protein, a dominant negative protein or no protein; or it can be a gene with one or more point mutations, resulting in an amino acid change in the encoded protein or resulting in abnormal splicing of the gene transcript.

[0024] The terms "mutant Taq DNA polymerase of the invention" and "mutant Taq DNA polymerase" when used in this Detailed Description section, depending on the context, refer collectively or individually to mutant Taq DNA polymerase polypeptides tested and exhibiting enhanced reverse transcriptase activity, as shown in Table I below (and above in the description of the figures), wherein for each mutant in Table I, the following odd-numbered sequence identifier is the DNA sequence, and the following even-numbered sequence identifier is the protein sequence, but does not include the tag sequence: GSGSSGHHHHHH (SEQ ID NO: 315) added to the C-terminus of the DNA encoding it. The terms "mutant Taq DNA polymerase of the invention" and "mutant Taq DNA polymerase" also include variant sequences and / or degenerate nucleic acid sequences, as these terms are defined in the Summary of the Invention section.

[0025] Table I

[0026] L15S (SEQ ID NO: 5; SEQ ID NO: 6), D18R (SEQ ID NO: 7; SEQ ID NO: 8), F66A (SEQ ID NO: 17; SEQ ID NO: 18), R85D (SEQ ID NO: 23; SEQ ID NO: 24), L108S (SEQ ID NO: 39; SEQ ID NO: 40), I138S (SEQ ID NO: 40) NO: 49; SEQ ID NO: 50), V155S (SEQ ID NO: 51; SEQ ID NO: 52), L156S ​​(SEQ ID NO: 53; SEQ ID NO: 54), K202E (SEQ ID NO: 73; SEQ ID NO: 74), K247E (SEQ ID NO: 95; SEQ ID NO: 96), E507G (SEQ ID NO: 95; SEQ ID NO: 96), NO:119; SEQ ID NO:120), E507L (SEQ ID NO:123; SEQ ID NO:124), T544I (SEQ ID NO:124) NO:127; SEQ ID NO:128), D578F (SEQ ID NO:131; SEQ ID NO:132), D732S (SEQ ID NO:151; SEQ ID NO:152), E742A (SEQ ID NO:153; SEQ ID NO:154), E742G (SEQ ID NO:155; SEQ ID NO:156), E742M (SEQ ID NO:161; SEQ ID NO:162), E742P (SEQ ID NO:163; SEQ ID NO:164) and E742S (SEQ ID NO:165; SEQ ID NO:166).

[0027] "Naturally occurring" or "wild-type" refers to the form found in nature. For example, a naturally occurring or wild-type polypeptide or polynucleotide sequence is a sequence that is present in an organism and has not been intentionally modified by human manipulation.

[0028] The term "percent identity" or "homology" with respect to nucleic acid or polypeptide sequences is defined as the percentage of nucleotides or amino acid residues in a candidate sequence that are identical to a known polypeptide after arranging the sequences to obtain the maximum percent identity and introducing a gap (if necessary) to achieve the maximum percent homology. N-terminal or C-terminal insertions or deletions should not be interpreted as affecting homology. Homology or identity at the nucleotide or amino acid sequence level can be determined by BLAST (Basic Local Alignment Search Tool) analysis using algorithms (Altschul (1997), Nucleic Acids Res [Nucleic Acids Research] 25, 3389-3402 and Karlin (1990), Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 87, 2264-2268) used by programs blastp, blastn, blastx, tblastn and tblastx, which are customized for sequence similarity searches. The method used by the BLAST program is to first consider similar fragments (with or without gaps) between the query sequence and the database sequence, then evaluate the statistical significance of all matches identified, and finally summarize only those matches that meet a pre-selected significance threshold. For a discussion of basic issues in sequence database similarity searches, see Altschul (1994), Nature Genetics [Natural Genetics] 6, 119-129. The search parameters for histograms, descriptions, alignments, expectations (i.e., statistical significance thresholds for reporting matches to database sequences), cutoffs, matrices, and filters (low complexity) can be default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff (1992), Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 89, 10915-10919), which is recommended for query sequences longer than 85 units (nucleotide bases or amino acids).

[0029] In some embodiments, the present invention relates to a method (and related kits, systems, apparatus and compositions) for performing a ligation reaction, the method comprising or consisting of contacting a mutant Taq DNA polymerase or a biologically active fragment thereof with a nucleic acid template in the presence of one or more nucleotides, and ligating at least one of the one or more nucleotides using the mutant Taq DNA polymerase or a biologically active fragment thereof.

[0030] In some embodiments, the method may include ligating a double-stranded RNA or DNA polynucleotide chain into a circular molecule. In some embodiments, the method may further include detecting a signal indicative of ligation using a sensor. In some embodiments, the sensor is an ISFET. In some embodiments, the sensor may include a detectable label or detectable reagent in the ligation reaction.

[0031] Preparation of mutant Taq DNA ligase

[0032] The mutant Taq DNA polymerase of the present invention can be expressed in any suitable host system, including bacterial, yeast, fungal, baculovirus, plant or mammalian host cells. For bacterial host cells, suitable promoters for directing transcription of the nucleic acid constructs of the present disclosure include promoters obtained from the following: E. coli lactose operon, Streptomyces coelicolor agarase gene (dagA), Bacillus subtilis sucrase gene (sacB), Bacillus licheniformis α-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens α-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis sucrase gene (sacB), Bacillus licheniformis α-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens α-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis sucrase gene (sacB), Bacillus licheniformis α-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens α-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis) xylA and xylB genes and a prokaryotic β-lactamase gene (Villa-Kamaroff et al., 1978, Proc. Natl Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 75:3727-3731), and the tac promoter (DeBoer et al., 1983, Proc. Natl Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 80:21-25).

[0033] For filamentous fungal host cells, suitable promoters for directing transcription of the nucleic acid constructs of the present disclosure include promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral α-amylase, Aspergillus niger acid-stable α-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (WO 96 / 00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the Aspergillus niger neutral α-amylase and Aspergillus oryzae triose phosphate isomerase genes), and mutants, truncations, and hybrid promoters thereof.

[0034] In yeast hosts, useful promoters can be derived from genes for the following enzymes: Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8:423-488.

[0035] For baculovirus expression, insect cell lines from the order Lepidoptera (moths and butterflies), such as Spodoptera frugiperda, are used as hosts. Gene expression is controlled by a strong promoter (e.g., pPolh).

[0036] Plant expression vectors are based on the Ti plasmid of Agrobacterium tumefaciens, or on tobacco mosaic virus (TMV), potato virus X or cowpea mosaic virus. A commonly used constitutive promoter in plant expression vectors is the cauliflower mosaic virus (CaMV) 35S promoter.

[0037] For mammalian expression, cultured mammalian cell lines such as Chinese hamster ovary (CHO), COS, including human cell lines such as HEK and HeLa, can be used to produce mutant Taq DNA polymerase. Examples of mammalian expression vectors include adenovirus vectors, pSV and pCMV series plasmid vectors, vaccinia virus and retroviral vectors and baculovirus. Cytomegalovirus (CMV) and SV40 promoters are commonly used in mammalian expression vectors to drive gene expression. Non-viral promoters, such as elongation factor (EF)-1 promoter are also known.

[0038] The control sequence for expression can also be a suitable transcription terminator sequence, i.e., a sequence recognized by the host cell to terminate transcription. The terminator sequence is operably linked to the 3' end of the nucleic acid sequence encoding the polypeptide. Any terminator that is functional in the selected host cell can be used.

[0039] For example, exemplary transcription terminators for filamentous fungal host cells can be obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.

[0040] Exemplary terminators for yeast host cells can be obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase.

[0041] Terminators for insect, plant, and mammalian host cells are also well known.

[0042] The control sequence can also be a suitable leader sequence, i.e. the non-translational region of the mRNA that is very important for the translation performed by the host cell. The leader sequence can be operably linked to the 5' end of the nucleotide sequence encoding the polypeptide. Any leader sequence with functionality in the selected host cell can be used. The exemplary leader sequence for filamentous fungal host cells is obtained from the genes of Aspergillus oryzae TAKA amylase and Aspergillus nidulans triosephosphate isomerase. The suitable leader sequence for yeast host cells is obtained from the following genes: Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae α-factor and Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP).

[0043] The control sequence can also be a polyadenylation sequence, a sequence that is operably linked to the 3' end of the nucleic acid sequence and is recognized by the host cell as a signal for adding polyadenylic acid residues to the transcribed mRNA when transcribed. Any polyadenylation sequence that is functional in the selected host cell can be used in the present invention. Exemplary polyadenylation sequences for filamentous fungal host cells can be derived from the genes for the following enzymes: Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase.

[0044] The control sequence may also be a signal peptide coding region that encodes an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide to enter the secretory pathway of a cell. The 5' end of the coding sequence of the nucleic acid sequence may itself contain a signal peptide coding region that is naturally linked in the translation reading frame to the segment of the coding region that encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence. In the case where the coding sequence does not naturally contain a signal peptide coding region, an exogenous signal peptide coding region may be required.

[0045] Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide. However, any signal peptide coding region that directs the expressed polypeptide into the secretory pathway of the selected host cell may be used.

[0046] Effective signal peptide coding regions for bacterial host cells are those obtained from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral protease (nprT, nprS, nprM), and Bacillus subtilis prs A. Further signal peptides are described by Simonen and Palva, 1993, Microbiol Rev [Microbiology Review] 57: 109-137.

[0047] An effective signal peptide coding region for a filamentous fungal host cell can be the signal peptide coding region obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.

[0048] Useful signal peptides for yeast host cells can be derived from the genes for Saccharomyces cerevisiae α-factor and Saccharomyces cerevisiae invertase.Signal peptides for other host cell systems are also well known.

[0049] The control sequence can also be a propeptide coding region encoding an amino acid sequence located at the amino terminus of a polypeptide. The resulting polypeptide is referred to as a proenzyme or propolypeptide (or in some cases as a zymogen). Propolypeptides are typically inactive and can be converted into mature active polypeptides by catalytic cleavage or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region can be obtained from the gene of the following enzyme: subtilis alkaline protease (aprE), subtilis neutral protease (nprT), saccharomyces cerevisiae α-factor, Rhizomucor miehei aspartic protease, and Myceliophthora thermophila lactase (WO 95 / 33836).

[0050] Where both the signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is located immediately adjacent to the amino terminus of the polypeptide and the signal peptide region is located immediately adjacent to the amino terminus of the propeptide region.

[0051] It is also desirable to add regulatory sequences that allow expression of mutant Taq DNA polymerases to be regulated relative to the growth of the host cell. Examples of regulatory systems are those that cause gene expression to be turned on or off in response to chemical or physical stimuli (including the presence of regulatory compounds). In prokaryotic host cells, suitable regulatory sequences include lac, tac, and trp operator systems. In yeast host cells, suitable regulatory systems include, for example, the ADH2 system or the GAL1 system. In filamentous fungi, suitable regulatory sequences include the TAKA alpha amylase promoter, the Aspergillus niger glucoamylase promoter, and the Aspergillus oryzae glucoamylase promoter. Regulatory systems for other host cells are also well known.

[0052] Other examples of regulatory sequences are those that allow gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene that is amplified in the presence of methotrexate and the metallothionein gene that is amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide of the present invention will be operably linked to the regulatory sequence.

[0053] Another embodiment comprises recombinant expression vector, it comprises the polynucleotide of coding through engineering approaches mutant Taq DNA polymerase or its variant, and one or more expression regulatory regions such as promoter and terminator, and replication origin, this depends on the type of the host that they will be introduced into.Above-mentioned various nucleic acid and control sequence can be linked together to produce recombinant expression vector, and described recombinant expression vector can comprise one or more convenient restriction sites to allow the insertion or replacement of the nucleotide sequence of encoding mutant Taq DNA polymerase at this type of site.Alternately, can be by inserting the nucleotide sequence of mutant Taq DNA polymerase in the appropriate vector for expressing by nucleotide sequence or the nucleic acid construct that comprises described sequence.When producing expression vector, coding sequence is positioned in carrier, makes coding sequence operably connected with the appropriate control sequence for expressing.

[0054] The recombinant expression vector can be any vector (e.g., plasmid or virus) that can be easily subjected to recombinant DNA procedures and can cause expression of the mutant Taq DNA polymerase polynucleotide sequence. The choice of vector will generally depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector can be a linear plasmid or a closed circular plasmid.

[0055] The expression vector can be an autonomously replicating vector, i.e., a vector existing as an extrachromosomal entity, and its replication does not depend on chromosome replication, such as a plasmid, an extrachromosomal element, a minichromosome or an artificial chromosome. The carrier can contain any means for ensuring self-replication. Alternatively, the carrier can be such a carrier, which is integrated into the genome and replicated together with one or more chromosomes into which it has been integrated when it is introduced into the host cell. In addition, a single carrier or plasmid or two or more carriers or plasmids containing the total DNA to be introduced into the host cell genome can be used, or a transposon can be used.

[0056] The expression vector herein preferably contains one or more selective markers, which allow for easy selection of transformed cells. A selective marker is a gene whose product provides biocide resistance or viral resistance, resistance to heavy metals, prototrophy to auxotrophic types, etc. Examples of bacterial selective markers are dal genes from Bacillus subtilis or Bacillus licheniformis, or markers that confer antibiotic resistance (such as ampicillin, kanamycin, chloramphenicol (Example 1) or tetracycline resistance). Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in filamentous fungal host cells include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenylyltransferase), and trpC (anthranilate synthase), and equivalents thereof. Embodiments for use in Aspergillus cells include the amdS and pyrG genes of Aspergillus nidulans or Aspergillus oryzae, and the bar gene of Streptomyces hygroscopicus. Selectable markers for use in insect, plant, and mammalian cells are also well known.

[0057] The expression vector of the present invention preferably contains one or more elements that allow the vector to be integrated into the genome of the host cell or the vector to replicate autonomously in the cell independently of the genome. For integration into the host cell genome, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for integration of the vector into the genome by homologous or non-homologous recombination.

[0058] Alternatively, the expression vector can contain other nucleotide sequences for guiding integration into the genome of the host cell by homologous recombination. Other nucleotide sequences enable the vector to be integrated into one or more precise locations of one or more chromosomes in the host cell genome. Integration elements can be any sequence homologous to the target sequence in the host cell genome. In addition, integration elements can be non-coding or encoding nucleic acid sequences. On the other hand, the vector can be integrated into the genome of the host cell by non-homologous recombination.

[0059] For autonomous replication, the vector may further include an origin of replication that enables the vector to autonomously replicate in the host cell in question. The example of a bacterial origin of replication is P15A ori, or the origin of replication of plasmids pBR322, pUC19, pACYC177 (the plasmid has P15A ori) or pACYC184 allowed to replicate in Escherichia coli, and the origin of replication of plasmids pUB110, pE194, pTA1060 or pAM31 allowed to replicate in bacillus. The example of the origin of replication used in yeast host cells is a combination of 2 microns of origin of replication, ARS1, ARS4, ARS1 and CEN3, and ARS4 and CEN6. The origin of replication can be an origin of replication with a mutation that makes its function in the host cell sensitive to temperature (see, e.g., Ehrlich, 1978, Proc Natl Acad Sci. USA [Proceedings of the National Academy of Sciences of the United States] 75:1433).

[0060] The nucleic acid sequence of more than one copy of the mutant Taq DNA polymerase can be inserted into the host cell to increase the production of the gene product. The copy number of the increase of the nucleic acid sequence can be obtained by integrating at least one other copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene together with the nucleic acid sequence, wherein cells containing amplified copies of the selectable marker gene and thus additional copies of the nucleic acid sequence can be selected by culturing the cells in the presence of an appropriate selective agent.

[0061] Expression vectors for mutant Taq DNA polymerase polynucleotides are commercially available. Suitable commercial expression vectors include p3xFLAGTM expression vectors from Sigma-Aldrich Chemicals, St.Louis Mo., including CMV promoter and hGH polyadenylation site for expression in mammalian host cells, and pBR322 replication origin and ampicillin resistance marker for amplification in Escherichia coli. Suitable other expression vectors are pBluescriptII SK (-) and pBK-CMV commercially available from Stratagene, La Jolla Calif., California, and plasmids derived from pBR322 (Gibco BRL), pUC (GibcoBRL), pREP4, pCEP4 (Invitrogen) or pPoly (Lathe et al., 1987, Gene [gene] 57: 193-201).

[0062] Suitable host cells for expressing polynucleotides encoding mutant Taq DNA polymerases are well known in the art, and include, but are not limited to, bacterial cells such as Escherichia coli, Lactobacillus kefir, Lactobacillus brevis, Lactobacillus microti, Streptomyces, and Salmonella typhimurium cells; fungal cells such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, BHK, 293, and Bowes melanoma cells; and plant cells. Suitable culture media and growth conditions for the above-mentioned host cells are well known in the art.

[0063] The polynucleotides for expressing mutant Taq DNA polymerase can be introduced into cells by various methods known in the art. These techniques include electroporation, biolistic particle bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion. Various methods for introducing polynucleotides into cells are known to the technician.

[0064] The polynucleotide encoding mutant Taq DNA polymerase can be prepared by a standard solid phase method according to known synthetic methods. In some embodiments, fragments of up to about 100 bases can be synthesized separately, and then connected (for example, by enzymatic or chemical connection methods, or polymerase-mediated methods) to form any desired continuous sequence. For example, the classical phosphoramidite method described by Beaucage et al., 1981, Tet Lett [tetrahedron express] 22: 1859-69, or by Matthes et al., 1984, EMBO J. [European Molecular Biology Journal] 3: 801-05 method described (for example, as it is generally used in automatic synthesis methods) and polynucleotides are prepared by chemical synthesis. According to the phosphoramidite method, oligonucleotides are synthesized, for example, in an automatic DNA synthesizer, purified, annealed, connected and cloned into a suitable vector. In addition, essentially any nucleic acid can be obtained from a variety of commercial sources, such as Midland Certified Reagent Company in Midland, Texas, Great American Gene Company in Ramona, California, ExpressGen in Chicago, Illinois, and Operon Technologies in Alameda, California.

[0065] The engineered mutant Taq DNA polymerase expressed in the host cell can be recovered from the cells and / or culture medium using any one or more of the well-known protein purification techniques, including lysozyme treatment, sonication, filtration, salting out, ultracentrifugation and chromatography. Suitable solutions for lysis and efficient protein extraction from bacteria such as E. coli are commercially available from Sigma-Aldrich, St. Louis, under the trade name CelLytic B.TM.

[0066] Chromatographic techniques used to separate mutant Taq DNA polymerases include reverse phase chromatography, high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, and affinity chromatography. Purification conditions will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, and will be apparent to those skilled in the art.

[0067] In some embodiments, affinity technology can be used to separate mutant Taq DNA polymerase.For affinity chromatography purification, any antibody that specifically binds mutant Taq DNA polymerase can be used.In order to produce antibodies, various host animals (including but not limited to rabbits, mice, rats, etc.) can be immunized by injection of compounds.Described compound can be attached to suitable carriers, such as BSA, by side chain functional groups or the joints attached to side chain functional groups.Various adjuvants can be used to enhance immune response, and this depends on host species, including but not limited to Freund's (Freund's) (completely and incompletely), mineral gels such as aluminum hydroxide, surfactants such as lysolecithin, complex polyols (pluronic polyols), polyanions, peptides, oil emulsions, keyhole limpet hemocyanin (keyhole limpet hemocyanin), dinitrophenol, and potentially useful people's adjuvants such as BCG (BCG) and Corynebacterium brevis.

[0068] Example of Preparation of Mutant Taq DNA Ligase

[0069] Taq DNA polymerase mutants that exhibited greater reverse transcriptase activity than the wild-type polymerase were engineered, characterized, and selected via polymerase chain reaction visualized via electrophoresis on agarose gels. Initial screening was followed up with a probe-based qualitative real-time fluorescence quantitative PCR (qPCR) that detected specific ribonucleic acid (RNA) target sequences using a typical reverse transcription cycling protocol.

[0070] Taq DNA polymerase mutants were generated by conventional inverse PCR mutagenesis. All mutants were sequenced, expressed in E. coli and purified. All Taq DNA polymerase mutants and wild type had an added C-terminal tag (SEQ ID NO: 315) to facilitate purification.

[0071] PCR was performed under the following conditions, wherein the target was the 28s gene.

[0072] Forward primer: CCGCTGCGGTGAGCCTTGAA (SEQ ID NO: 313)

[0073] Reverse primer: TCTCCGGGATCGGTCGCGTT (SEQ ID NO: 314)

[0074] Target: 28s RNA, 10 ng from total RNA - human tumor cell line: Hela (Biochain Cat. No. R1255811-50).

[0075] Each 10 μl reaction contained 1.5 μl of 50 ng / μl Taq DNA polymerase, 0.4 μl of 10 nM forward primer, 0.4 μl of 10 nM reverse primer, 1 μl of 10 copies / μl of target RNA, 0.4 μl of 10 nM equimolar dNTPs, 0.1 μl of 1 M DDT, and 1 μl of 10x reaction buffer (the final composition of which was 20 mM Tris-HCl, 80 mM Tris-acetate, 10 mM (NH 4 ) 2 SO 4 , 10 mM KCl, 2 mM MgSO 4 , 3mM Mg-acetate, 0.1% pH 8.8 (at 25°C)), the remaining 10 μl was made up with water.

[0076] The thermal cycler used for this PCR assay is Bio-Rad T100. The reaction scheme is as follows: 60°C incubation for 20 minutes, 95°C denaturation for 5 minutes, followed by 35 cycles [95°C denaturation for 10 seconds, 60°C extension for 30 seconds], followed by incubation for 5 min at 75°C. 3ul of 6X stop dye containing 6X GelRed nucleic acid stain (Biotium catalog number 41003) is added to each sample. Each 10 μl of sample is loaded into 2% agarose gel, and compared to low molecular weight DNA ladder markers (New England Biolabs, catalog number N3233) with WT Taq polymerase.

[0077] The results are shown in Figures 1 to 5The wild type result (WT) (SEQ ID NO: 2) is also shown in each figure, but it did not show any significant amplification.

[0078] qPCR Uses of Mutant Taq DNA Polymerases

[0079] Figures 1 to 5 The mutant Taq DNA polymerase in can be used to quantify RNA in a sample using a conventional qPCR protocol for RNA detection without the need to add an additional reverse transcriptase to the reaction mixture. In the case of qualitative real-time PCR (qPCR), the fluorescent signal generated by a dye (e.g., an intercalating dye such as SYBR Green or Eva Green) or a probe allows data to be collected during the PCR cycle so that target amplification can be measured and recorded. Probe-based chemistry utilizes fluorescently labeled target-specific probes that release a reporter dye only when bound to the target sequence, thereby allowing real-time detection of target amplification as the intensity of the fluorescent signal increases. The standard qPCR reaction mixture includes a reaction buffer (typically, similar to 20mM Tris-HCl, 80mM Tris-acetate, 10mM (NH 4 ) 2 SO 4 , 10 mM KCl, 2 mM MgSO 4 , 3mM Mg-acetate, 0.1% pH 8.8 (at 25°C), with water constituting the remainder. A qPCR machine is preferably used for the reaction, such as a Prime Pro 48 real-time qPCR machine (Cole-Parmer, UK). The reaction protocol including the number of cycles, denaturation, and annealing time and temperature is well established. A fluorescent signal that can be measured is generated. See U.S. Publication No. 20220106576 (incorporated by reference).

[0080] The wild-type sequence and the sequence of a mutant showing enhanced reverse transcription activity are shown below, each sequence having a tag sequence (SEQ ID NO: 315) added to its C-terminus.

[0081] Wild-type and mutant Taq DNA polymerase sequences

[0082] DNA sequence of Taq DNA polymerase with a C-terminal His tag (L15S) (SEQ ID NO: 5)

[0083] Protein sequence of Taq DNA polymerase with a C-terminal His tag (L15S) (SEQ ID NO: 6)

[0084] DNA sequence of Taq DNA polymerase with a C-terminal His tag (D18R) (SEQ ID NO: 7)

[0085] Protein sequence of Taq DNA polymerase with a C-terminal His tag (D18R) (SEQ ID NO: 8)

[0086] DNA sequence of Taq DNA polymerase with a C-terminal His tag (F66A) (SEQ ID NO: 17)

[0087] Protein sequence of Taq DNA polymerase with a C-terminal His tag (F66A) (SEQ ID NO: 18)

[0088] DNA sequence of Taq DNA polymerase with a C-terminal His tag (R85D) (SEQ ID NO: 23)

[0089] Protein sequence of Taq DNA polymerase with a C-terminal His tag (R85D) (SEQ ID NO: 24)

[0090] DNA sequence of Taq DNA polymerase with a C-terminal His tag (L108S) (SEQ ID NO: 39)

[0091] Protein sequence of Taq DNA polymerase with a C-terminal His tag (L108S) (SEQ ID NO: 40)

[0092] DNA sequence of Taq DNA polymerase with a C-terminal His tag (I138S) (SEQ ID NO: 49)

[0093] Protein sequence of Taq DNA polymerase with a C-terminal His tag (I138S) (SEQ ID NO: 50)

[0094] DNA sequence of Taq DNA polymerase with a C-terminal His tag (V155S) (SEQ ID NO: 51)

[0095] Protein sequence of Taq DNA polymerase with a C-terminal His tag (V155S) (SEQ ID NO: 52)

[0096] DNA sequence of Taq DNA polymerase with a C-terminal His tag (L156S) (SEQ ID NO: 53)

[0097] Protein sequence of Taq DNA polymerase with a C-terminal His tag (L156S) (SEQ ID NO: 54)

[0098] DNA sequence of Taq DNA polymerase with a C-terminal His tag (K202E) (SEQ ID NO: 73)

[0099] Protein sequence of Taq DNA polymerase with a C-terminal His tag (K202E) (SEQ ID NO: 74)

[0100] DNA sequence of Taq DNA polymerase with a C-terminal His tag (K247E) (SEQ ID NO: 95)

[0101] Protein sequence of Taq DNA polymerase with a C-terminal His tag (K247E) (SEQ ID NO: 96)

[0102] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E507G) (SEQ ID NO: 119)

[0103] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E507G) (SEQ ID NO: 120)

[0104] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E507L) (SEQ ID NO: 123)

[0105] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E507L) (SEQ ID NO: 124)

[0106] DNA sequence of Taq DNA polymerase with a C-terminal His tag (T544I) (SEQ ID NO: 127)

[0107] Protein sequence of Taq DNA polymerase with a C-terminal His tag (T544I) (SEQ ID NO: 128)

[0108] DNA sequence of Taq DNA polymerase with a C-terminal His tag (D578F) (SEQ ID NO: 131)

[0109] Protein sequence of Taq DNA polymerase with a C-terminal His tag (D578F) (SEQ ID NO: 132)

[0110] DNA sequence of Taq DNA polymerase with a C-terminal His tag (D732S) (SEQ ID NO: 151)

[0111] Protein sequence of Taq DNA polymerase with a C-terminal His tag (D732S) (SEQ ID NO: 152)

[0112] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E742A) (SEQ ID NO: 153)

[0113] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E742A) (SEQ ID NO: 154)

[0114] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E742G) (SEQ ID NO: 155)

[0115] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E742G) (SEQ ID NO: 156)

[0116] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E742M) (SEQ ID NO: 161)

[0117] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E742M) (SEQ ID NO: 162)

[0118] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E742P) (SEQ ID NO: 163)

[0119] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E742P) (SEQ ID NO: 164)

[0120] DNA sequence of Taq DNA polymerase with a C-terminal His tag (E742S) (SEQ ID NO: 165)

[0121] Protein sequence of Taq DNA polymerase with a C-terminal His tag (E742S) (SEQ ID NO: 166)

[0122] The specific methods and compositions described herein are representative of preferred embodiments, and are exemplary and are not intended to limit the scope of the invention. In view of this specification, other purposes, aspects and embodiments will occur to those skilled in the art, and are included in the spirit of the invention as defined by the scope of the claims. It will be apparent to those skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention described illustratively herein may be appropriately practiced in the absence of any one or more elements, or any one or more restrictions, that are not explicitly disclosed herein as necessary. Thus, for example, in each case herein, in the embodiments or examples of the present invention, any of the terms "comprising", "including", "containing", etc. should be read broadly and without restriction. The methods and processes exemplarily described herein may be appropriately implemented in different step orders, and they are not necessarily limited to the step orders indicated herein or in the claims. It should also be noted that, unless the context clearly indicates otherwise, as used herein and in the appended claims, the singular forms "one / a kind" and "said" include plural indicators, and the plural includes the singular form. In any case, this patent application cannot be interpreted as being limited to the specific examples or embodiments or methods specifically disclosed herein.

[0123] The present invention has been described broadly and generally herein. Each of the narrower species and subgeneric classifications falling within the total disclosure also forms a part of the present invention. The terms and expressions that have been adopted are used as terms of description and are not restrictive, and are not intended to exclude any equivalents or portions thereof of the features shown and described using such terms and expressions, but it will be appreciated that different modifications within the scope of the invention claimed are possible. Therefore, it should be understood that, although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and changes of the concepts disclosed herein may be adopted by those skilled in the art, including but not limited to variant sequences, and such modifications and changes are considered to be within the scope of the invention defined by the appended claims.

[0124] Other references:

[0125] 1.Kranaster R,Drum M,Engel N,Weidmann M,Hufert FT,Marx A.One-step RNApathogen detection with reverse transcriptase activity of a mutatedthermostable Thermus aquaticus DNA polymerase.Biotechnol J.2010Feb;5(2):224-31.doi:10.1002 / biot.200900200.PMID:20108275.

[0126] 2.Bhadra S,Maranhao AC,Paik I,Ellington AD.One-Enzyme ReverseTranscription qPCR Using Taq DNAPolymerase.Biochemistry.2020Dec 15;59(49):4638-4645.doi:10.1021 / acs.biochem.0c00778.Epub 2020Dec 4.PMID:33275410;PMCID:PMC7757722.

[0127] 3.Barnes WM,Zhang Z,Kermekchiev MB.A Single Amino Acid Change to TaqDNA Polymerase Enables Faster PCR,Reverse Transcription and Strand-Displacement.Front Bioeng Biotechnol.2021Jan 14;8:553474.doi:10.3389 / fbioe.2020.553474.PMID:33520948;PMCID:PMC7841393。

Claims

1. A mutant Taq polymerase comprising one or more of the following amino acid mutations set forth in the odd-numbered sequence below, and wherein the remainder of the mutant polymerase has at least 80% amino acid sequence identity to a wild-type Taq polymerase as set forth in SEQ ID NO:2, but wherein the wild-type Taq polymerase does not comprise a 6-membered histidine tag and immediately preceding 6-membered glycine and serine amino acids at its C-terminus: L15S (SEQ ID NO:5; SEQ ID NO:6), D18R (SEQ ID NO:7; SEQ ID NO:8), F66A (SEQ ID NO:17; SEQ ID NO:18), R85D (SEQ ID NO:23; SEQ ID NO:24), L108S (SEQ ID NO:39; SEQ ID NO:40), I138S (SEQ ID NO:49; SEQ ID NO:50), V155S (SEQ ID NO:51; SEQ ID NO:52), L156S ​​(SEQ ID NO:53), NO:53; SEQ ID NO:54), K202E (SEQ ID NO:73; SEQ ID NO:74), K247E (SEQ ID NO:95; SEQ ID NO:96), E507G (SEQ ID NO:119; SEQ ID NO:120), E507L (SEQ ID NO:123; SEQ ID NO:124), T544I (SEQ ID NO:127; SEQ ID NO:128), D578F (SEQ ID NO:131; SEQ ID NO:132), D732S (SEQ ID NO:151; SEQ ID NO:152), E742A (SEQ ID NO:153; SEQ ID NO:154), E742G (SEQ ID NO:154) NO:155; SEQ ID NO:156), E742M (SEQ ID NO:161; SEQ ID NO:162), E742P (SEQ ID NO:163; SEQ ID NO: 164) and E742S (SEQ ID NO: 165; SEQ ID NO: 166).

2. The Taq DNA polymerase according to claim 1, which has at least 90% sequence identity with the wild type.

3. A DNA sequence encoding the mutant Taq polymerase according to claim 1.

4. A vector incorporating one or more of the DNA sequences according to claim 3.

5. A cell transformed with and expressing one or more of the DNA sequences according to claim 3. The mutant Taq DNA polymerase according to claim 1 , wherein the mutant Taq polymerase is capable of reverse transcribing mRNA to produce cDNA.

7. The mutant Taq DNA polymerase of claim 6, wherein the reverse transcription of mRNA to produce cDNA occurs through 38 or more amplification cycles.

8. The mutant Taq DNA polymerase of claim 6, wherein reverse transcription of mRNA to produce cDNA occurs to a significantly greater extent than by wild-type Taq DNA polymerase under the same conditions.

9. A reverse transcription PCR method, comprising: A reverse transcription PCR mixture is provided, the reverse transcription PCR mixture comprising an RNA target, a target sequence primer, and a mutant Taq DNA polymerase, the mutant Taq DNA polymerase having one or more of the following amino acid mutations shown in the following odd-numbered sequence, and wherein the remainder of the mutant polymerase has at least 80% amino acid sequence identity with a wild-type Taq polymerase, the wild-type Taq polymerase being as shown in SEQ ID NO:2, but wherein the wild-type Taq polymerase does not comprise a 6-membered histidine tag at its C-terminus and the immediately preceding 6-membered glycine and serine amino acids: L15S (SEQ ID NO:5; SEQ ID NO:6), D18R (SEQ ID NO:7; SEQ ID NO:8), F66A (SEQ ID NO:17; SEQ ID NO:18), R85D (SEQ ID NO:23; SEQ ID NO:24), L108S (SEQ ID NO:39; SEQ ID NO:40), I138S (SEQ ID NO:49; SEQ ID NO:50), V155S (SEQ ID NO:51; SEQ ID NO:52), ID NO:51; SEQ ID NO:52), L156S ​​(SEQ ID NO:53; SEQ ID NO:54), K202E (SEQ ID NO:73; SEQ ID NO:74), K247E (SEQ ID NO:95; SEQ ID NO:96), E507G (SEQ ID NO:119; SEQ ID NO:120), E507L (SEQ ID NO:119; SEQ ID NO:120) ID NO:123; SEQ ID NO:124), T544I (SEQ ID NO:127; SEQ ID NO:128), D578F (SEQ ID NO:131; SEQ ID NO:132), D732S (SEQ ID NO:151; SEQ ID NO:152), E742A (SEQ ID NO:153; SEQ ID NO:154), E742G (SEQ ID NO:155; SEQ ID NO:156), E742M (SEQ ID NO:161; SEQ ID NO:162), E742P (SEQ ID NO:163; SEQ ID NO:164) and E742S (SEQ ID NO:165; SEQ ID NO:166); subjecting the reverse transcription PCR mixture to PCR cycling conditions to produce cDNA; as well as The amount of cDNA produced is detected to quantify the RNA target.

10. The method of claim 9, wherein the amount of cDNA is detected by determining the amount of a reporter signal generated by an intercalating dye or by cleavage of a labeled target probe.

11. A reverse transcription qPCR method, comprising: A reverse transcription qPCR mixture is provided, the reverse transcription qPCR mixture comprising an RNA target, a target sequence primer, an intercalating dye or a labeled target probe, and a mutant Taq DNA polymerase, the labeled target probe fluorescing when the label is cleaved from the probe by exonuclease activity, the mutant Taq DNA polymerase having one or more of the following amino acid mutations shown in the following odd-numbered sequence, and wherein the remainder of the mutant polymerase has at least 80% amino acid sequence identity with a wild-type Taq polymerase, the wild-type Taq polymerase being as shown in SEQ ID NO:2, but wherein the wild-type Taq polymerase does not comprise a 6-membered histidine tag at its C-terminus and immediately preceding 6-membered glycine and serine amino acids: L15S (SEQ ID NO:5; SEQ ID NO:6), D18R (SEQ ID NO:7; SEQ ID NO:8), F66A (SEQ ID NO:17; SEQ ID NO:18), R85D (SEQ ID NO:23; SEQ ID NO:24), L108S (SEQ ID NO:39; SEQ ID NO:40), NO:40), I138S (SEQ ID NO:49; SEQ ID NO:50), V155S (SEQ ID NO:51; SEQ ID NO:52), L156S ​​(SEQ ID NO:53; SEQ ID NO:54), K202E (SEQ ID NO:73; SEQ ID NO:74), K247E (SEQ ID NO:95; SEQ ID NO:96), E507G (SEQ ID NO:119; SEQ ID NO:120), E507L (SEQ ID NO:123; SEQ ID NO:124), T544I (SEQ ID NO:127; SEQ ID NO:128), D578F (SEQ ID NO:131; SEQ ID NO:132), D732S (SEQ ID NO:132) NO:151; SEQ ID NO:152), E742A (SEQ ID NO:153; SEQ ID NO:154), E742G (SEQ ID NO:154) NO:155; SEQ ID NO:156), E742M (SEQ ID NO:161; SEQ ID NO:162), E742P (SEQ ID NO:163; SEQ ID NO:164) and E742S (SEQ ID NO:165; SEQ ID NO:166); The annealing temperature provides sufficient time to anneal the primer from the target; Provide a certain number of cycles of annealing temperature followed by extension temperature; as well as The amount of reporter signal generated by cleavage of the intercalating dye or the labeled target probe is determined to quantify the amount of RNA target sequence present in the qPCR mixture.

12. The qPCR method of claim 11, wherein there are 38 or more cycles.

13. The qPCR method of claim 11, wherein the reporter signal is fluorescent. The qPCR method according to claim 11 , wherein the intercalating dye is SYBR Green or Eva Green.

Citation Information

Patent Citations

  • Taq DNA Polymerase Mutants for Probe qPCR

    US20220106576A1

  • Phosphonyldipeptides useful in the treatment of cardiovascular diseases

    WO1995033836A1

  • Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein

    WO1996000787A1

  • T4 DNA ligase variant with increased ligation efficiency

    CN114934026A

  • Taq DNA polymerase mutant and application thereof

    CN115044569A